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seasonal malaria chemoprevention, previously known as intermittent preventive treatment in 
children, is highly effective in areas with a short malaria transmission season. Here we assess 
seasonality in malaria incidence data and define a predictor of seasonality based on rainfall. 
We then use spatial rainfall, malaria endemicity and population data to identify areas likely to 
have highly seasonal malaria incidence, and estimate the population at risk and malaria burden 
in areas where seasonal malaria chemoprevention would be appropriate. We estimate that 
in areas suitable for seasonal malaria chemoprevention, there are 39 million children under 
5 years of age, who experience 33.7 million malaria episodes and 152,000 childhood deaths 
from malaria each year. The majority of this burden occurs in the sahelian or sub-sahelian 
regions of Africa. our data suggest that seasonal malaria chemoprevention has the potential 
to avert several million malaria cases and tens of thousands of childhood deaths each year if 
successfully delivered to the populations at risk. 
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Child mortality remains unacceptably high in many countries in sub-Saharan Africa, with malaria being a major contribu-tor to this burden. Current estimates of malaria morbidity 
in Africa range from 174 million to 271 million clinical cases each 
year1,2, resulting in 600,000 to 1.1 million deaths1,3. Although there 
are uncertainties and limitations attached to each of these estimates, 
the burden of malaria is clearly unacceptably high and new malaria 
control measures are urgently needed, particularly for African 
children under 5 years of age.
A series of studies conducted in Sahelian and sub-Sahelian Africa 
have shown that seasonal malaria chemoprevention (SMC), previ-
ously known as intermittent preventive treatment of malaria in chil-
dren (IPTc), is a promising tool for the control of malaria in areas 
where transmission of malaria is highly seasonal. A meta-analysis of 
SMC studies in which a therapeutic course of sulphadoxine-pyrimeth-
amine plus amodiaquine (SP-AQ) was given once per month to chil-
dren under the age of 5 years during the peak malaria transmission 
season showed an 83% (95% CI: 72%, 89%) reduction in the inci-
dence of clinical attacks of malaria and a similar reduction in the 
incidence of severe malaria (77%; 95% CI: 45%, 90%)4. Similar find-
ings were obtained in a recent Cochrane review of IPTc studies5. The 
SP-AQ combination used in most trials was safe. Current evidence is 
consistent with a reduction in all-cause mortality due to SMC but the 
confidence intervals are wide (A.L.W., unpublished results)4,5. Simi-
lar results have been obtained with other antimalarial combinations 
given on a monthly basis. Administration every 2 months has also 
been tried but was less effective6. High levels of coverage have been 
achieved using community health workers to administer SMC, and 
the intervention is highly cost effective7,8. In the majority of studies, 
three monthly administrations have been employed and, although 
longer periods of administration may be considered, the evidence in 
relation to feasibility of delivery, safety and efficacy of SMC relates 
primarily to administration over a 3-month period.
The World Health Organization (WHO) convened a meeting of a 
Technical Expert Group in May 2011 to consider whether sufficient 
data had been gathered to recommend incorporation of SMC into 
the malaria control programmes of areas with highly seasonal trans-
mission of malaria. Their positive recommendation was reviewed 
by a newly constituted WHO Malaria Policy Advisory Committee 
in February 2012. If SMC with SP-AQ is formally recommended as 
policy by the Malaria Policy Advisory Committee, implementation 
may begin in certain countries of the Sahel and sub-Sahel sometime 
in 2012. Malaria control programme managers will need to consider 
whether regions of their country are suitable for the implementation 
of SMC on the basis of the incidence of malaria and its seasonality 
in those regions. To assist policy makers and programme manag-
ers in making such decisions, we have identified the geographical 
areas where SMC is likely to be an appropriate and cost-effective 
intervention using data on the overall incidence and seasonality of 
malaria in different parts of sub-Saharan Africa.
In this study, we show that there are two large areas of Africa 
likely to have both sufficient seasonality and sufficient malaria 
incidence for SMC to be both effective and cost-effective. In par-
ticular, the Sahelian and sub-Sahelian regions of Africa have a large 
population of children under 5 years of age at risk in areas where 
SMC with current antimalarials is likely to be highly efficacious, and 
where millions of malaria cases and tens of thousands of childhood 
deaths could potentially be prevented each year.
Results
Defining areas suitable for the implementation of SMC. Fifty-
six sites where monthly malaria incidence had been measured for 
12 consecutive months were identified in 22 sub-Saharan African 
countries (Supplementary Tables S1,2). Areas meeting seasonality 
definition B (60% of annual incidence within 4 consecutive months) 
were observed more frequently in the Sahel and sub-Sahel than in 
other parts of Africa. Definition B gave consistent results in sites 
where more than one type of malaria outcome had been recorded 
(for example, severe malaria and clinical malaria) or where 
information was available for several years. Definition C (50% of 
annual incidence in 4 months) was not stringent enough to identify 
SMC areas, as a large number of sites had this level of seasonality. 
Definition A (75% of annual incidence in 4 months) excluded several 
sites known to be highly seasonal, including sites in the Gambia and 
Senegal, suggesting that this definition is too strict. Definition B 
was, therefore, used for subsequent analyses.
After inspection of site-specific rainfall patterns, the severe malaria 
data reported for one site were considered unreliable (seasonality in 
malaria incidence was much stronger than the seasonality in rain-
fall), and this site was excluded as an outlier; 55 sites were, therefore, 
available for analysis (Supplementary Tables S1,2). The best predictor 
of sufficient seasonality for SMC according to definition B was  > 60% 
of the total annual rainfall within three consecutive months; this 
cutoff identified areas with incidence patterns suitable for SMC with 
a sensitivity of 95.0% and a specificity of 73.5% (Fig. 1).
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Figure 1 | Analysis of rainfall as a predictor of epidemiology suitable 
for SMC. (a) Receiver operating characteristic curve for binary indicator 
variables describing the percentage of the annual total rainfall occurring 
in 3 consecutive months. Dummy variables were created for 5% intervals 
between 0% and 100%. observed values of cumulative rainfall in 3 
months ranged from 33.8%–84.5%. The best indicator of smC areas was 
rainfall greater than 60% in 3 months (sensitivity 95.0%, specificity of 
73.5%). The black line indicates the reference line of no discrimination. 
(b) maximum percentage of annual rainfall within 3 consecutive months 
compared with maximum percentage of malaria incidence within four 
consecutive months. The horizontal red line shows the cumulative 
incidence threshold within 4 months specified by definition B. The vertical 
red line shows discrimination of the data points by the best indicator based 
on rainfall (60% within 3 months).
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Maps produced by rainfall seasonality alone, and by rainfall 
seasonality in areas endemic for Plasmodium falciparum, identi-
fied two broad areas as being potentially suitable for deployment of 
SMC (Fig. 2a,b). The first includes much of the Sahelian and sub- 
Sahelian regions of Africa, which matches well with the sites identi-
fied from the seasonality assessment of epidemiological data. The 
second area is in southern Africa, stretching from Namibia in the 
west to Mozambique and Southern Tanzania in the east.
Estimating the population and burden in SMC areas. The geo-
graphical area mapped by rainfall seasonality, as defined above, in 
malaria endemic areas led to an estimate of 39 million children under 
5 years of age at risk of malaria in areas suitable for implementation 
of SMC, 24.9 million in the Sahel or sub-Sahel and 14.1 million in 
southern and eastern Africa. On the basis of this population at risk, 
the method used in the World Malaria Report 2008 (WMR)9 gave 
a total burden estimate of 33.7 million cases per year in children 
under 5 years of age in sites suitable for SMC, 24.1 million cases 
in the Sahel and sub-Sahel, and 9.6 million per year in the rest of 
Africa (Table 1). The burden estimate using a prevalence-incidence 
relationship derived by the Malaria Atlas Project (MAP)10 was 12 
million malaria cases (see Methods), 8.5 million of these in the Sahel 
and sub-Sahel. Mortality estimates using a fixed case fatality rate 
were 151,552 (108,506 in the Sahel and sub-Sahel) for the WMR 
burden estimate and 53,953 (38,474 in the Sahel and sub-Sahel) for 
the MAP burden estimate. Use of a population-based mortality rate, 
as described by Rowe et al.11 gave an estimate of 314,283 deaths from 
malaria (221,811 in the Sahel and sub-Sahel). Applying a higher case 
fatality rate of 10 per 1,000 gave similar estimates to those produced 
using the method of Rowe et al.11 (data not shown).
The burden in SMC areas above minimum incidence thresholds. 
Applying lower prevalence thresholds to the map of areas suitable 
for SMC (Fig. 2c,d) produced smaller population estimates (Tables 2 
and 3): 28.9 million children under 5 years of age at risk in areas 
with incidence greater than 0.1 episodes per child during the trans-
mission peak (21 million in the Sahel and sub-Sahel) and 24.9 mil-
lion children at risk in areas with 0.2 episodes per child during the 
transmission peak (18.9 million in the Sahel and sub-Sahel). Cor-
responding morbidity and mortality estimates were slightly lower 
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Figure 2 | Areas suitable for SMC implementation based on seasonality in rainfall and on malaria endemicity. (a). The maximum proportion of annual 
rainfall occurring within three consecutive months. orange-red areas are those identified as suitable for smC based on  > 60% of annual rainfall in 3 months. 
Green–blue areas indicate areas with less than 60% of annual rainfall within 3 months. First administrative level areas are superimposed on the map. (b) The 
maximum proportion of annual rainfall restricted to areas with stable endemic P. falciparum, as estimated by mAP21. (c) and (d) indicate rainfall seasonality 
in areas with prevalence above 8.8 and 17.3%, as estimated by mAP, corresponding to incidence above 0.1 and 0.2 cases per child per year, respectively.
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but remained substantial, particularly in the Sahel and sub-Sahel. 
The most stringent incidence threshold of 0.2 episodes per child 
during the transmission peak resulted in an estimate of 25.7 mil-
lion malaria cases and 115,704 deaths (18.9 million cases and 85,225 
deaths in the Sahel and sub-Sahel).
Estimating the potential public health impact of SMC. Using the 
WMR estimate of 33.7 million malaria cases per year in children 
under 5 years of age in the areas mapped as suitable for SMC, and 
151,552 deaths per year (applying the fixed case fatality rate (CFR) 
to the incidence estimate), SMC is predicted to have a consider-
able impact (Fig. 3). Restricting estimates to areas with incidence 
greater than 0.2 cases per child per year made only relatively minor 
changes. Even if our approach has resulted in a 50% overestimate 
of the malaria burden in SMC areas, the potential impact of SMC 
could still be substantial, with ~5 million cases and 20,000 deaths 
averted if the intervention was widely deployed (Table 4).
Discussion
We have defined the epidemiological settings where SMC is 
likely to be a suitable intervention and mapped the geographical 
areas where this epidemiology is likely to be found. Climate-
based predictors identified the highly seasonal areas suitable for 
SMC with high sensitivity and good specificity. It is clear from 
our estimates that there is a large population of children under 
5 years of age at risk from malaria in areas where SMC is likely 
to be appropriate. The burden of malaria in these areas, particu-
larly in countries in the Sahel and sub-Sahel, is substantial and 
suggests that SMC deployed at scale could have a major public 
health impact.
Most evidence on the efficacy of SMC relates to delivery over 
3 months. We chose to focus on incidence during a period of 4 con-
secutive months as this is the longest period for which 3 monthly 
courses of SMC might be expected to provide a reasonably high 
level of protection. Our assumption of impact during a 4-month 
peak was conservative as this was based on estimates of protective 
efficacy obtained from a study of children sleeping under insecti-
cide treated nets over a three-and-a-half month follow-up period, 
assuming no protection in the subsequent two weeks.
Although a considerable number of studies were identified in the 
literature review, only a small proportion of these reported morbidity 
data in the required format to assess seasonality in malaria burden 
Table 1 | Estimated populations at risk, malaria incidence and malaria deaths in areas suitable for SMC.
Country Total 
population*
Population 
in SMC 
zone*
Under 5 
population in 
SMC zone†
Urban under 5 
population in 
SMC areas‡ 
Malaria Cases Malaria Deaths
Incidence 
WMR 
method
Incidence 
MAP 
function
Fixed CFR: 
WMR 
burden
Fixed 
CFR: MAP 
burden
Population- 
based rate
Benin 8,812,518 557,092 92,422 21,829 115,740 49,723 521 224 986
Burkina Faso 15,708,964 13,854,376 2,710,747 1,227,218 2,977,936 1,609,070 13,401 7,241 27,098
Cameroon 19,126,809 2,950,626 460,947 208,160 390,087 181,627 1,755 817 3,586
Chad 10,912,155 6,976,680 1,250,849 393,004 1,311,052 346,358 5,900 1,559 11,486
Gambia 1,852,882 1,852,882 291,403 197,020 273,908 38,212 1,233 172 2,711
Ghana 24,501,245 177,859 24,934 14,930 24,461 14,999 110 67 235
Guinea 10,574,798 5,995,674 986,348 435,741 1,083,751 305,363 4,877 1,374 9,829
Guinea-
Bissau
1,562,554 1,560,768 259,868 122,311 280,761 40,546 1,263 182 2,570
mali 13,117,059 12,098,009 2,096,706 690,613 2,274,587 1,055,338 10,236 4,749 20,001
mauritania 3,597,585 3,241,751 468,790 177,407 242,195 51,038 1,090 230 2,208
niger 14,436,029 14,075,787 3,030,517 1,205,408 3,106,105 1,065,640 13,977 4,795 27,882
nigeria 145,248,683 37,671,263 6,135,519 3,190,591 6,413,956 2,902,822 28,863 13,063 59,756
senegal 13,481,010 13,472,934 2,235,833 1,338,423 2,168,117 236,238 9,757 1,063 20,817
sierra Leone 6,629,124 2,563,964 430,567 296,715 400,413 165,589 1,802 745 3,985
sudan 42,415,970 32,087,735 4,397,303 2,037,863 3,049,119 487,319 13,721 2,193 28,661
Total sahel 331,977,385 149,137,400 24,872,753 11,557,233 24,112,188 8,549,882 108,506 38,474 221,811
Angola 13,421,810 766,121 130,830 57,207 76,552 29,324 344 132 717
Botswana 1,890,943 254,308 29,118 6,478 304 3,118 1 14 1
Democratic 71,412,940 1,871,914 335,466 287,543 234,090 86,198 1,053 388 2,521
Eritrea 5,333,163 4,254,536 691,703 327,522 208,594 25,707 939 116 2,117
Ethiopia 81,845,206 19,799,829 3,219,848 1,536,402 597,487 179,261 2,689 807 5,773
Kenya 39,835,135 330,420 55,620 32,748 14,428 843 65 4 142
malawi 14,825,033 14,581,686 2,490,552 1,047,864 2,233,686 1,046,546 10,052 4,709 20,329
mozambique 22,526,159 13,858,809 2,286,704 537,017 2,759,878 1,185,143 12,419 5,333 23,553
namibia 2,126,549 1,411,821 179,654 62,411 3,480 33,268 16 150 16
Tanzania 42,861,827 8,882,815 1,580,253 496,524 1,468,064 372,383 6,606 1,676 12,946
Zambia 12,393,193 11,235,159 2,007,835 793,611 1,938,396 399,162 8,723 1,796 17,425
Zimbabwe 12,276,732 8,087,013 1,107,355 516,048 30,829 78,571 139 354 6,932
Total other 320,748,690 85,334,431 14,114,938 5,701,375 9,565,788 3,439,524 43,046 15,479 92,472
Total Africa 652,726,075 234,471,831 38,987,691 17,258,608 33,677,976 11,989,406 151,552 53,953 314,283
Abbreviations: CFR, case fatality rate; mAP, malaria Atlas Project; smC, seasonal malaria chemoprevention in children; WmR, World malaria Report.
Estimated populations at risk, malaria cases and malaria deaths in the area where  > 60% of total annual rainfall occurs in 3 months & P. falciparum is endemic.
*Estimate from Landscan 2007, scaled up to 2010 as described in the text.
 †Estimated using percentage aged 0–4 in united nations World Population Prospects 2008, using estimates for 2010.
 ‡% urban estimated from population density.
Population-based rate: estimate of malaria mortality calculated as in Rowe et al.11detailed in WmR 2008, that is, directly from the population at risk according to endemicity and urbanicity (see Table 5).
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reliably. Nevertheless, enough data points were found to explore the 
utility of different cutoffs to define malaria incidence as sufficiently 
seasonal for SMC to be valuable. As previously reported12, in sites with 
2 rainy seasons, the largest number of cases per month did not neces-
sarily occur in 4 consecutive months (Supplementary Tables S1,2). 
Therefore, some situations where SMC may be appropriate, if 
directed at two seasonal peaks in transmission, may not have been 
identified by the approach used here. However, to date, SMC has 
not been used in such settings; whether this would be appropriate 
requires further investigation. Our approach focusses on epidemio-
logical situations with a single peak in transmission, situations in 
which the efficacy of SMC has already been well characterized.
Rainfall patterns delineated two distinct geographical areas where 
SMC could be considered. The estimates of populations of SMC 
areas defined in our analyses are consistent with the populations 
living in seasonal transmission areas determined by the Mapping 
Malaria Risk in Africa project13, but are more conservative (Supple-
mentary Tables S3,4). The map incorporating malaria endemicity 
is more biologically plausible than one based on rainfall alone as it 
excludes areas where rainfall may be seasonal but very low, or where 
other conditions prohibit malaria transmission. Malaria control 
programmes operating in countries bordering the area identified 
as being suitable for SMC should undertake assessment of the 
seasonality of malaria in these areas, using local incidence data to 
guide decisions about whether deployment of SMC would be appro-
priate. For example, rainfall in most of northern Ghana did not 
meet the seasonality criterion and our estimate of the population 
at risk in Ghana is consequently relatively small. However, the 
epidemiology of malaria in Navrongo, Ghana suggests that 
the northern regions may be suitable for SMC (Supplementary 
Tables S1,2)14. Therefore, it is likely that a larger area could poten-
tially benefit from SMC and a larger population could be protected 
than we have defined in this study.
The continental maps showing areas suitable for SMC implemen-
tation covered primarily Sahelian and sub-Sahelian areas as expected 
a priori. Areas meeting the seasonality criterion were also found in 
southern and eastern Africa, where there is much less epidemiologi-
cal information on the seasonality of malaria. In some of these areas, 
the incidence of malaria is low and unstable and therefore SMC is 
not likely to be a suitable intervention. Incidence thresholds, based 
on cost per case and per disability-adjusted life year averted, indi-
cated that SMC might still be worthwhile in some areas, particularly 
in southern Tanzania, Malawi and northern Mozambique, but this 
needs further investigation. For SMC to be deployed in southern 
and eastern Africa, an alternative to the SP-AQ combination would 
be needed owing to high levels of SP resistance15.
The difficulties in estimating the malaria burden in Africa accu-
rately are well recognized3,9,11,16–18. Our emphasis was to derive 
a plausible and conservative estimate of the malaria burden using 
transparent methods, rather than aiming to produce an alternative 
estimate to those provided by others. However, burden estimates 
based on different approaches showed broadly consistent figures. 
The estimates using the MAP prevalence–incidence function were 
lowest, but it is clear from comparison with data from SMC sites 
Table 2 | Impact of incidence thresholds on populations at risk and malaria burden estimates.
Country Areas with incidence  > 0.1 per child during peak season
Total under  
5 population in 
SMC area
Incidence WMR 
method
Incidence MAP 
function
Fixed CFR: WMR 
burden
Fixed CFR: MAP 
burden
Population- 
based rate
Benin 92,422 115,740 49,723 521 224 986
Burkina Faso 2,710,747 2,977,936 1,609,070 13,401 7,241 27,098
Cameroon 460,947 390,087 181,627 1,755 817 3,586
Chad 1,233,923 1,292,068 345,010 5,814 1,553 11,325
Gambia 167,845 181,733 30,180 818 136 1,666
Ghana 24,934 24,461 14,999 110 67 235
Guinea 953,662 1,045,331 302,643 4,704 1,362 9,492
Guinea-Bissau 132,768 161,251 30,103 726 135 1,391
mali 2,092,353 2,269,493 1,054,989 10,213 4,747 19,957
mauritania 126,116 77,422 35,599 348 160 652
niger 3,030,517 3,106,105 1,065,640 13,977 4,795 27,882
nigeria 6,135,519 6,413,956 2,902,822 28,863 13,063 59,756
senegal 782,446 901,870 177,640 4,058 799 7,913
sierra Leone 430,567 400,413 165,589 1,802 745 3,985
sudan 2,211,932 1,709,930 389,225 7,695 1,752 15,282
Total sahel 20,586,698 21,067,796 8,354,859 94,805 37,596 191,206
Angola 107,291 66,912 28,190 301 127 609
Botswana 15,187 159 2,124 1 10 1
DR Congo 335,466 234,090 86,198 1,053 388 2,521
Eritrea 42,504 14,149 4,576 64 21 140
Ethiopia 214,202 46,822 30,282 211 136 423
malawi 2,485,962 2,229,121 1,046,185 10,031 4,708 20,289
mozambique 2,286,704 2,759,878 1,185,143 12,419 5,333 23,553
namibia 147,318 2,854 30,964 13 139 13
Tanzania 969,689 934,674 340,939 4,206 1,534 8,097
Zambia 1,438,054 1,485,260 368,877 6,684 1,660 12,913
Zimbabwe 260,528 7,253 41,705 33 188 1,819
Total other 8,302,905 7,781,172 3,165,183 35,016 14,244 70,378
Total Africa 28,889,603 28,848,968 11,520,042 129,821 51,840 261,584
Abbreviations: CFR, case fatality rate; mAP, malaria Atlas Project; smC, seasonal malaria chemoprevention in children; WmR, World malaria Report.
Estimated populations population under 5 years of age, malaria burden and malaria deaths in areas defined by prevalence above 8.8%, as estimated by mAP, corresponding to incidence above 0.1 
cases per child per year. Population-based rate: estimate of malaria mortality calculated as in Rowe et al.11detailed in WmR 2008, that is, directly from the population at risk according to endemicity and 
urbanicity (see Table 5).
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that these are likely to be an underestimate as the function relates 
prevalence in children to all-age incidence rather than incidence 
in children under 5 years of age. Furthermore, the estimates pro-
duced using the WMR method were similar to those derived using 
a prevalence–incidence function fitted specifically to incidence data 
on children under 5 years of age (Griffin J., personal communica-
tion). Our estimate of the impact of SMC on mortality is simplistic, 
assuming that a reduction in malaria cases would be accompanied 
by a proportional reduction in malaria deaths. However, our esti-
mates of impact do not include the reductions in indirect mortality 
that may result from better control of malaria.
Some of the areas with the highest malaria burden in all of Africa 
lie within the parts of the Sahel and sub-Sahel, which we have iden-
tified as being suitable for SMC2. Deployment of SMC in these areas 
would be expected to be highly cost effective on the basis of the high 
malaria incidence per child each year. The coverage and efficacy that 
would be achieved, if SMC was to be implemented as a large-scale 
public health measure, is not yet known, but high coverage has been 
achieved by community-based health workers7, and efficacy should 
remain high where SP and AQ resistance levels remain low or 
moderate. Furthermore, our analysis suggests that even with mod-
erate levels of coverage, the deployment of SMC could have a signifi-
cant public health impact.
The epidemiological and geographical situations in which SMC 
is likely to be useful can be defined on the basis of epidemiological 
data and surrogate measures of seasonality in malaria transmission. 
A simple algorithm could be developed to help policy makers to 
decide whether the malaria incidence in their country, or cer-
tain regions within their country, was sufficiently seasonal for the 
deployment of SMC. The algorithm could also indicate the potential 
impact of implementation of SMC with different levels of efficacy 
and coverage. Although the burden of malaria in the areas where 
SMC could be deployed is uncertain, it is likely to be considerable. 
Our analyses suggest that even where other effective malaria con-
trol tools, such as insecticide-treated nets (ITNs), indoor residual 
spraying of insecticides (IRS) and partially effective malaria vac-
cines are deployed, SMC could potentially avert a very large number 
of malaria episodes and many thousands of unnecessary deaths 
in several countries where malaria is currently not adequately 
controlled.
Methods
Defining SMC seasonality. We performed a literature review to identify studies 
reporting incidence of parasitologically confirmed clinical malaria and/or severe 
malaria for 12 consecutive months. Sources of data used included published 
monthly malaria incidence data obtained from a systematic review conducted in 
2005 (refs 12,19), surveillance data and an additional systematic review undertaken 
in 2010, including contact with authors. Search criteria and further details are 
included in Supplementary Methods, Supplementary Table S5 and Supplementary 
Fig. S1. Locations of the sites are shown in Supplementary Figs S2,3.
A previous analysis indicated that ≥75% of malaria incidence occurring within 
6 consecutive months provided a useful definition of ‘marked seasonality’12. Most 
of the evidence for the efficacy and safety of SMC relates to monthly delivery over 
a 3-month period, which provided protection during a transmission peak of 3-to-4 
Table 3 | Impact of incidence thresholds on populations at risk and malaria burden estimates.
Country Areas with incidence  > 0.2 per child, during peak season
Total under  
5 population in 
SMC area
Incidence WMR 
method
Incidence MAP 
function
Fixed CFR: WMR 
burden
Fixed CFR: MAP 
burden
Population- based 
rate
Benin 92,422 115,740 49,723 521 224 986
Burkina Faso 2,710,747 2,977,936 1,609,070 13,401 7,241 27,098
Cameroon 460,947 390,087 181,627 1,755 817 3,586
Chad 987,539 1,095,101 300,360 4,928 1,352 9,334
Gambia 49,756 56,268 13,281 253 60 504
Ghana 24,934 24,461 14,999 110 67 235
Guinea 864,219 939,217 288,038 4,226 1,296 8,567
Guinea-Bissau 56,488 71,788 19,128 323 86 606
mali 2,053,160 2,219,292 1,048,925 9,987 4,720 19,549
mauritania 93,389 57,805 30,919 260 139 485
niger 2,984,561 3,065,522 1,057,632 13,795 4,759 27,488
nigeria 6,135,519 6,413,956 2,902,822 28,863 13,063 59,756
senegal 350,480 433,664 115,751 1,951 521 3,675
sierra Leone 430,567 400,413 165,589 1,802 745 3,985
sudan 835,372 677,804 178,652 3,050 804 5,929
Total sahel 18,130,100 18,939,054 7,976,516 85,225 35,894 171,783
Angola 69,179 47,600 21,286 214 96 415
Botswana 488 5 104 0 0 0
DR Congo 134,301 107,869 51,916 485 234 1,072
Eritrea
Ethiopia 30,799 7,124 7,157 32 32 63
malawi 2,437,874 2,182,455 1,038,567 9,821 4,674 19,881
mozambique 2,262,968 2,733,653 1,181,343 12,301 5,316 23,320
namibia 86,500 1,676 21,760 8 98 8
Tanzania 700,354 679,556 300,247 3,058 1,351 5,869
Zambia 974,151 1,011,944 301,004 4,554 1,355 8,774
Zimbabwe 49,661 1,383 13,220 6 59 353
Total other 6,746,275 6,773,265 2,936,604 30,479 13,215 59,755
Total Africa 24,876,375 25,712,319 10,913,120 115,704 49,109 231,538
Abbreviations: CFR, case fatality rate; mAP, malaria Atlas Project; smC, seasonal malaria chemoprevention in children; WmR, World malaria Report.
Estimated populations population under 5 years of age, malaria burden and malaria deaths in areas defined by prevalence above 17.3%, as estimated by mAP, corresponding to incidence above 0.2 
cases per child per year. Population-based rate: estimate of malaria mortality calculated as in Rowe et al.11detailed in WmR 2008, that is, directly from the population at risk according to endemicity and 
urbanicity (see Table 5).
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months. We therefore explored different definitions of the degree of seasonality 
based on the maximum percentage of the total annual malaria burden occurring 
within any consecutive four-month period. Three definitions were considered: at 
least 75% (definition A), 60% (definition B) and 50% (definition C) of the total 
annual incidence of malaria within four consecutive months.
Identifying spatial predictors of SMC areas. To characterize seasonality in 
malaria incidence outside the areas, for which epidemiological data were available, 
we explored whether rainfall patterns, estimated from a combination of satel-
lite imagery and rain gauge data20, could be used as a predictor of the degree of 
seasonality in incidence. Daily accumulated rainfall data were available for a grid of 
0.1 degree×0.1 degree resolution, with data missing for only 2 days since November 
2000. We used data from 2002 to 2009 and aggregated the daily time series to time 
series using 64 points per year. Fourier analyses were undertaken to capture the 
average seasonality over this time period.
Each site identified by our review was geo-referenced and site-specific rainfall 
data obtained. For each location of interest, we selected the pixel closest to the 
given longitude/latitude. The percentage (in 5% intervals) of the annual total  
rainfall occurring in a range of different consecutive periods (ranging from 2 to  
6 months) was then calculated to create a set of potential indicators of seasonality. 
The sensitivity and specificity of each indicator variable as a predictor of the degree 
of seasonality in malaria incidence was calculated to create receiver operating char-
acteristic (ROC) curves using Stata 11 software (College Station, Texas, USA).
The best predictor of seasonality in malaria incidence was then used to map 
areas suitable for SMC across Africa using the 0.1 degree×0.1 degree grid of rainfall 
data. For each pixel, the seasonality in rainfall was calculated by assessing the 
maximum percentage of the total annual rainfall occurring in a period of consecu-
tive months. Pixels meeting the criterion specified by the best indicator variable 
were considered as potentially suitable for SMC. To further improve the biological 
plausibility of the spatial mapping of SMC areas, we merged the map produced by 
seasonality in rainfall with spatial malaria endemicity estimates produced by MAP 
for 2010 (ref. 21), restricting the area mapped by seasonality in rainfall to include 
only areas with stable P. falciparum transmission (annual incidence of P. falciparum 
infections  > 0.1 per 1,000 population per annum).
Estimating the population and burden in SMC areas. The total population at risk 
in the areas identified by the approach described above was derived from LandScan 
2007 population estimates22. Population estimates were aggregated within first 
administrative level and then by country, and scaled to 2010 by applying national 
growth rates from UN projections23. We estimated the number of children under  
5 years of age using UN demographic information for each country23 and the  
percentage living in urban/rural areas based on a population density threshold24. 
For full details, see Supplementary Methods. Malaria incidence in children under  
5 years of age in SMC areas was estimated using two published methods (Table 5).  
The first follows the approach used in the 2008 WMR for countries where estimates 
of malaria incidence could not be made from routinely reported data9,25. Fixed 
age-specific incidence rates were used according to the level of malaria risk as 
defined by the Mapping Malaria Risk in Africa map, and in high-transmission 
areas, incidence estimates were halved for populations living in urban areas13. To 
retain transparency, incidence estimates were not reduced further to account for 
coverage of other malaria control tools; the possible impact of interventions such 
as ITNs and IRS are considered in a sensitivity analysis. The second method used a 
published function relating annual all-age incidence to prevalence of parasitaemia 
in children 2–10 years of age10. We applied the central estimate of this function 
to the MAP prevalence data to estimate incidence (Fig. 4). The effect of urban 
residence is incorporated in the prevalence estimates2 and is, therefore, implicitly 
accounted for. By comparison with observed incidence/prevalence observations 
made in SMC studies, this relationship is likely to result in a conservative estimate 
of the incidence of malaria in children under 5 years of age during the transmission 
peak for a given prevalence (Fig. 4).
The mortality burden in SMC areas was also estimated by two approaches (Table 
5). Method one assumes a fixed CFR of 4.5 deaths per 1,000 malaria cases (0.45%), 
the central estimate for areas where malaria morbidity is routinely reported9. This 
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Figure 3 | Malaria cases and deaths potentially averted by SMC. malaria 
cases and malaria deaths potentially averted in all areas suitable for smC 
(a,c), and in areas with incidence  > 0.2 cases per child per year (b,d), with 
varying assumptions about efficacy, monthly coverage and the fraction  
of the burden occurring during the smC period. 75% was considered the 
best estimate of the fraction of the total annual malaria burden occurring 
during the smC period in smC areas; 60 and 90% are also shown. solid 
lines show impact for 3 smC courses, assumed to have 65% efficacy  
as detailed in the text. Dotted lines show impact for 4 smC courses,  
assumed to have 80% efficacy. The malaria burden estimate used for 
these calculations was that using the WmR method: 33,677,976 malaria 
cases in all smC areas with stable endemic P. falciparum, and 25,712,319 
derived from the population mapped by rainfall in areas with estimate of 
malaria incidence  > 0.2/child/year. Deaths refer to the constant-case 
fatality rate of 4.5 per 1,000, applied to the incidence estimates.
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fixed CFR was applied to incidence estimates derived using both the WMR method 
and the MAP incidence–prevalence function. We also explored a higher case fatality 
rate of 10 per 1,000 (that is, 1% fatality rate). Method 2 uses the approach of Rowe 
et al., applying a fixed mortality rate to populations at risk rather than to malaria 
cases11. For simplicity, we did not amend our estimates to take account of the 
relative contribution of malaria to all-cause under 5 mortality, as performed in the 
WMR, but this would only be expected to reduce the estimates by ~10% (ref. 9).
The burden in SMC areas above minimum incidence thresholds. Analysis of 
the costs of SMC delivery undertaken by the IPTc Working Group suggests that, 
on the basis of both costs per case averted and cost per disability-adjusted life 
year averted, SMC is likely to be cost-effective where malaria incidence exceeds 
0.2. episodes per child during the peak transmission season, but may not be cost 
effective where incidence is less than 0.1 episodes per child during the transmis-
sion peak (Pitt C, Milligan P, unpublished results). The MAP incidence–prevalence 
relationship suggests that incidence would be at least 0.1 episodes per child per 
season at a prevalence of parasitaemia  > 8.8%, and at least 0.2 episodes per child at 
a prevalence  > 17.3%. Using these cutoffs is likely to be highly conservative because 
incidence in children at a given prevalence is likely to be substantially higher 
than all age incidence, the prediction given by the MAP function (Fig. 4). These 
minimum prevalence thresholds were used to map a restricted SMC area, giving a 
conservative estimate of the population at risk and of morbidity and mortality in 
areas where SMC would be appropriate on the basis of sufficiently high incidence.
Table 5 | Summary of methods used to estimate incidence of 
clinical episodes of malaria and malaria mortality.
Rural areas Urban areas
malaria Incidence
  method 1 (WmR 
method)
   High 
transmission*
1.42 per person, per year 0.71 per person, 
per year
   Low 
transmission†
0.18 per person, per year 0.18 per person, 
per year
  southern Africa‡ 0.029 per person,  
per year
0.029 per person, 
per year
 method 2 (mAP) Published prevalence-
incidence function used10
malaria Deaths
 method 1
   Case-fatality 
rate of 4.5 per 
1,000 malaria 
cases in all areas
 method 2
   High 
transmission
11.4/1,000 population 8.3/1,000 
population
   Low 
transmission
2.3/1,000 population 1.8/1,000 
population
*Climate suitability for malaria greater than 0.75, according to mARA data.
†Climate suitability 0.25–0.75, according to mARA data.
‡southern Africa : south Africa, swaziland, Botswana, namibia and Zimbabwe.
For certain countries in southern Africa with low malaria risk (only relevant to Botswana and 
namibia in our analysis), method 2 is not used for mortality. Estimates from method 1 were 
used for these countries.
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Figure 4 | Prevalence and incidence of malaria detected in SMC studies 
and the MAP prevalence-incidence relationship. Data points show 
observed incidence against end of season prevalence from control or 
placebo groups in IPTc studies from niakhar, senegal30; Hohoe, Ghana31; 
Kambila, mali32; Bobo-Dioulasso, Burkina Faso (Zongo I., personal 
communication); Kati, mali27 and Boussé, Burkina Faso26. Data points 
show malaria incidence defined as fever plus parasitaemia of any density 
or with a local defined parasite density cutoff, and are shown against the 
left vertical axis. All studies included children under 5 years of age, with 
the exception of the Kambila IPTc study, which included children under 10 
years of age. For the Kambila IPTc study (mali) the prevalence estimate 
at the start of the transmission season (92/262, 35.1%) was used rather 
than that measured at the end of the transmission season, as this was 
based on relatively small numbers (8/54, 15%). The curve shows the 
fitted relationship between all age incidence per annum and prevalence in 
children 2–10 years of age, 13 and is shown against the right vertical axis. 
Dashed lines show the upper and lower limit of the incidence-prevalence 
relationship defined by the IPTc data points.
Table 4 | Sensitivity analysis of cases and deaths potentially averted by SMC.
All SMC areas SMC areas with incidence  
 > 0.1/child/year
SMC areas with incidence  
 > 0.2/child/year
Cases averted Deaths averted Cases averted Deaths averted Cases averted Deaths averted
3 SMC courses
 50% overestimate 5,746,305 25,858 4,922,355 22,151 4,387,164 19,742
 25% overestimate 8,619,457 38,788 7,383,533 33,226 6,580,747 29,613
 Best estimate 11,492,609 51,717 9,844,710 44,301 8,774,329 39,484
 25% underestimate 14,365,762 64,646 12,305,888 55,376 10,967,911 49,356
 50% underestimate 17,238,914 77,575 14,767,065 66,452 13,161,493 59,227
4 SMC courses
 50% overestimate 7,072,375 31,826 6,058,283 27,262 5,399,587 24,298
 25% overestimate 10,608,562 47,739 9,087,425 40,893 8,099,380 36,447
 Best Estimate 14,144,750 63,651 12,116,567 54,525 10,799,174 48,596
 25% underestimate 17,680,937 79,564 15,145,708 68,156 13,498,967 60,745
 50% underestimate 21,217,125 95,477 18,174,850 81,787 16,198,761 72,894
Cases and deaths that could potentially be averted by smC with different assumptions about the accuracy of the burden estimate, ranging from a 50% overestimate to a 50% underestimate. For 
illustration, 70% coverage of smC monthly treatment courses is assumed. Efficacy is assumed to be either 65% (3 courses of smC) or 80% (4 courses of smC), with 75% of the annual burden occur-
ring during the smC period. The malaria burden estimates used were those derived using the WmR method (33,677,976 28,848,968 and 25,712,319 malaria cases for the 3 areas). Deaths refer to the 
estimate calculated applying the constant-case fatality rate of 4.5 per 1,000 to the incidence estimate.
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Estimating the potential public health impact of SMC. We considered the number 
of cases and deaths that could potentially be averted with different levels of SMC 
efficacy and coverage. In sites considered suitable for SMC, the median fraction of 
incidence occurring in the 4 consecutive months of peak transmission was 77% and 
the mean 75.7% (Supplementary Table S1,2). We therefore assumed that, on average, 
75% of the annual burden occurred in the SMC period, but also explored the impact 
of SMC, if 60% and 90% of annual incidence occurred in the period when SMC was 
given. In recent studies of SMC in Burkina Faso and Mali, protective efficacy of 3, 
monthly courses over a period of three-and-a-half months from the date of the first 
course was 70% and 82% respectively26,27. On the basis of these figures, assuming no 
protective effect in the two weeks after the end of the follow-up, the protective effi-
cacy over four months would be 61% (Burkina) and 72% (Mali), a mean of 67%. We 
therefore assumed that a protective efficacy of 65% would be a reasonable estimate 
of protection provided by three courses over a 4-month peak. Four monthly courses 
over 4 months might provide protective efficacy of ~80%.
We explored the potential range in impact of SMC by allowing for a 25 or 50% 
underestimate or overestimate of the malaria burden without SMC. We accounted 
for a possible overestimate in this way to include the burden estimate that would be 
expected, had we additionally adjusted for coverage of other widely used malaria 
control tools. ITNs and IRS would be estimated to reduce incidence by ~50% and 
60%, respectively, at 100% coverage9,28. However, actual coverage of these interven-
tions is currently far less than 100% in most African countries29. 
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